Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: A prospective and randomized study

被引:20
作者
Akaza, H [1 ]
Homma, Y [1 ]
Okada, K [1 ]
Yokoyama, M [1 ]
Moriyama, N [1 ]
Usami, M [1 ]
Hirao, Y [1 ]
Tsushima, T [1 ]
Ohashi, Y [1 ]
Aso, Y [1 ]
机构
[1] Univ Tsukuba, Dept Urol, Inst Clin Med, Tsukuba, Ibaraki 3050006, Japan
关键词
control study; hormone therapy; LH-RH agonist; localized or locally advanced prostate cancer; randomized;
D O I
10.1093/jjco/hyd035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The majority of patients with localized and some cases of locally advanced prostate cancer undergo radical prostatectomy. However, radical prostatectomy cannot always be selected for those patients. In this situation, primary hormone therapy is an alternative treatment option. We have designed a prospective randomized study of the effects of primary hormone therapy for such patients. Methods: A total of 151 patients with T1b, T1c, T2a, T2b or T3a prostate cancer who were not scheduled for radical prostatectomy were enrolled into this study. Patients were randomly allocated into two groups; Group I received luteinizing hormone-releasing hormone (LH-RH) agonist monotherapy (leuprorelin acetate depot, 3.75 mg monthly) and Group II received LH-RH agonist in combination with chlormadinone acetate (100 mg/day). Effects on serum prostate-specific antigen level, progression-free survival and survival were observed for 2 years. Results: The reasons why radical prostatectomy was not scheduled were poor risk for surgery (38%), patient's wish (32%) and physician's recommendation (30%). After 12 weeks of treatment, 49% of the patients in both groups showed a complete response (CR). Of the patients showing a partial response (PR) after 12 weeks of treatment, 25% in Group I and 52% in Group II improved to CR 1 year later (p < 0.05). Group II showed a longer progression-free survival (p < 0.05). Progression-free survival rates were 62% (Group I) and 91%(Group II) in T2b patients and 43% (Group I) and 73% (Group II) in T3 patients. Only one patient in each group died from prostate cancer. Conclusions: Early primary hormone therapy is a reasonable treatment option for localized or locally advanced prostate cancer patients if radical prostatectomy was not scheduled. Chlormadinone acetate showed an additive effect with LH-RH agonist, at least in 2 years' observation.
引用
收藏
页码:131 / 136
页数:6
相关论文
共 18 条
[1]  
AKAZA H, 1992, JPN J CLIN ONCOL, V22, P177
[2]  
Akaza H, 1996, Int J Urol, V3, P468, DOI 10.1111/j.1442-2042.1996.tb00578.x
[3]   A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA [J].
CRAWFORD, ED ;
EISENBERGER, MA ;
MCLEOD, DG ;
SPAULDING, JT ;
BENSON, R ;
DORR, FA ;
BLUMENSTEIN, BA ;
DAVIS, MA ;
GOODMAN, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :419-424
[4]   Maximal androgen blockade: Final analysis of EORTC phase III trial 30853 [J].
Denis, LJ ;
Keuppens, F ;
Smith, PH ;
Whelan, P ;
de Moura, JLC ;
Newling, D ;
Bono, A ;
Sylvester, R .
EUROPEAN UROLOGY, 1998, 33 (02) :144-151
[5]  
Fourcade R O, 1998, Int J Urol, V5, P303, DOI 10.1111/j.1442-2042.1998.tb00356.x
[6]   TOTAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATIC-CANCER - LONG-TERM RESULTS [J].
GIBBONS, RP ;
CORREA, RJ ;
BRANNEN, GE ;
WEISSMAN, RM .
JOURNAL OF UROLOGY, 1989, 141 (03) :564-566
[7]   Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation - Authors' reply [J].
Homma, Y .
INTERNATIONAL JOURNAL OF UROLOGY, 1999, 6 (05) :238-239
[8]  
Homma Y, 1997, Int J Urol, V4, P144, DOI 10.1111/j.1442-2042.1997.tb00161.x
[9]  
*JAP UR ASS JAP PA, 1992, GEN RUL CLIN PATH ST
[10]   HIGH 10-YEAR SURVIVAL RATE IN PATIENTS WITH EARLY, UNTREATED PROSTATIC-CANCER [J].
JOHANSSON, JE ;
ADAMI, HO ;
ANDERSSON, SO ;
BERGSTROM, R ;
HOLMBERG, L ;
KRUSEMO, UB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16) :2191-2196